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Abstract 
 
Rationale Methylone, a new drug of abuse sold as “bath salts" has similar effects to 
ecstasy or cocaine. 
 
Objective We have investigated changes in dopaminergic and serotoninergic markers, 
indicative of neuronal damage, induced by methylone in the frontal cortex, 
hippocampus and striatum of mice and according two different treatment schedules.  
 
Methods Methylone was given subcutaneously to male Swiss CD1 mice and at an 
ambient temperature of 26ºC. Treatment A: three doses of 25 mg/Kg at 3.5 h interval 
between doses for two consecutive days. Treatment B: four doses of 25 mg/Kg at 3 h 
interval in one day. 
 
Results Repeated methylone administration induced hyperthermia and a significant 
loss in body weight.  Following treatment A, methylone induced transient dopaminergic 
(frontal cortex) and serotoninergic (hippocampus) impairment. Following treatment B, 
transient dopaminergic (frontal cortex) and serotonergic (frontal cortex and 
hippocampus) changes 7 days after treatment were found. We found evidence of 
astrogliosis in the CA1 and the dentate gyrus of the hippocampus following treatment 
B. The animals also showed an increase in immobility time in the forced swim test, 
pointing to a depressive-like behavior. In cultured cortical neurons, methylone (for 24 
and 48 h) did not induce a remarkable cytotoxic effect.  
 
Conclusions The neural effects of methylone differ depending upon the treatment 
schedule. Neurochemical changes elicited by methylone are apparent when 
administered at an elevated ambient temperature, four times per day at 3 h intervals, 
which is in accordance with its short half-life. 
 
 
Keywords: Methylone. Neurotoxicity. Striatum. Frontal cortex. Hippocampus. Mice 
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Introduction  
The illegal status of the classic psychostimulants (particularly MDMA and cocaine) has 
encouraged users to seek newer drugs that have become increasingly available 
through the Internet, which allows effective marketing, sale and distribution and is the 
major reason for the increase in their availability (Brandt et al., 2010; McElrath and O’ 
Neill, 2011; Karila and Reynaud, 2010). 
Synthetic modifications of cathinone, structurally similar to amphetamine and 
extracted from the leaves of khat, have led to a number of so-called designer cathinone 
derivatives sold as “bath salts”. The most commonly available cathinones appear to be 
mephedrone (4-methyl-methcathinone) and methylone (3,4-methylene-
dioxymethcathinone) (Brunt et al., 2011). Methylone was first synthesized as an 
antidepressant but, around 2004, emerged as a recreational drug under the trade 
name “explosion”, and was one of the first products of this nature to be marketed on-
line (Bossong et al., 2005). It is taken by the oral or intranasal route. 
Methylone shows a strong structural and pharmacological similarity to MDMA, but 
little is known about its particular pharmacology. Results from in vitro studies 
hypothesized that methylone acted similarly to d-amphetamine (Cozzi et al., 1999; 
Baumann et al., 2012), by binding to monoamine transporters (Nagai et al., 2007; 
Simmler et al., 2013). Recently, studies have been published on the pharmacological 
targets of cathinones by our group (Martínez-Clemente et al., 2012; López-Arnau et al., 
2012) and others (Kehr et al., 2011; Hadlock et al., 2011; Motbey et al., 2011) 
demonstrating that methylone acts on monoaminergic systems. Moreover, in vitro 
studies reveal that cathinone derivatives are non-selective substrates for monoamine 
transporters, which lead to reuptake blockage and enhancement of the release of 
monoamines by reversing the flow of the transporter, which results in elevated synaptic 
neurotransmitter levels (Sogawa et al., 2011; Baumann et al., 2012; Simmler et al., 
2013; Eshleman et al., 2013). This is a critical point since only transporter substrates 
(and not uptake inhibitors) are capable of causing long-term deficits in monoamine cells 
(Fleckenstein et al., 2007). 
Human data on methylone abuse are obtained from consumer reports (Shimizu et 
al., 2007; Boulanger-Gobeil et al., 2012). On-line reports indicate that 100-250 mg in 
each intake is a common oral dose of methylone and users evidenced a desire to re-
dose, leading them to ingest large quantities of the drug. Fatal intoxications due to 
methylone have been described (Pearson et al., 2012) with elevated body temperature 
and symptoms similar to sympathomimetic toxicity, including metabolic acidosis, 
rhabdomyolysis, acute renal failure and disseminated intravascular coagulation. The 
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authors concluded that peripheral blood methylone concentrations greater than 0.5 
mg/L may be lethal. 
Not only is the rise in abuse of methylone of concern, but so is the lack of 
experimental data on the neurotoxicity of methylone in rodents. MDMA produces 
species-dependent neurotoxicity (Logan et al., 1988), and there is reason to suspect 
that methylone would display a similar effect. In keeping with this, some species 
differences in the sensitivity to long-term neurochemical effects of methylone have 
been shown. Hollander et al. (2013) described no effects of methylone on serotonin (5-
HT) levels in mice, but a widespread depletion of 5-HT and 5-HT transporter levels in 
rats was evidenced. Moreover, Baumann et al. (2012) found no effect of methylone on 
monoamine levels two weeks after treatment, also in rats, although they concluded that 
the effects of methylone and other cathinones should be evaluated in assays 
measuring 5-HT deficits, for example, with high-dose administrations.  
The aim of this paper is to investigate methylone-induced neurochemical changes in 
mice that are indicative of neurotoxicity, addressing some of the limitations found in the 
literature on the subject to date. Any information that may lead to suspicion regarding 
the neurotoxicity or safety of methylone is critical. Experiments were carried out at a 
high ambient temperature simulating hot conditions found in dance clubs where 
amphetamine derivatives are usually consumed (Senn et al., 2007). We have 
evaluated the in vivo effect of this cathinone using different dosage schedules and in 
different brain areas assessed by decreases in the density of DA or 5-HT uptake sites 
and the enzyme that catalyzes the first and rate-limiting step in the biosynthesis of both 
neurotransmitters. Other outcome measures included drug-induced changes in body 
weight, core body temperature, depressive behavior and glial activation. Although mice 
or rats do not provide an exact model of methylone-induced neurotoxicity for humans, 
the present study intends to broaden our understanding of the adverse effects of this 
cathinone derivative. 
 
Materials and methods 
Drugs and reagents 
Racemic and pure methylone HCl was synthetized and characterized by us in our 
department’s organic chemistry laboratory, under authorization from the University of 
Barcelona as described previously (López-Arnau et al., 2012). The rest of drugs were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). [3H]ketanserin, [3H]paroxetine and 
[3H]WIN35428 were from Perkin Elmer (Boston, MA, USA). All buffer reagents were of 
analytical grade. 
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Animals 
The experimental protocols for the use of animals in this study were approved by the 
Animal Ethics Committee of the University of Barcelona under the supervision of the 
Autonomous Government of Catalonia, following the guidelines of the European 
Community Council (86/609/EEC). Male Swiss CD-1 mice (Charles River, Spain) 
weighing 25-30 g and aged 4-5 weeks were used. Animals were housed at 22 ± 1 ºC 
under a 12 h light/dark cycle with free access to food and drinking water. All the 
endpoints were taken in different animals. 
 
In vivo neurotoxicity assays 
The doses used in the present study were chosen according to available Internet 
information (www.erowid.org) and literature (Hollander et al., 2013; Simmler et al., 
2013) and were calculated following to the FDA (Food and Drug Administration, Center 
for Drug Evaluation and Research, 2005) guidelines. No information is available on 
subcutaneous doses in humans. A dose of 150-200 mg in a 60-70 kg human yields a 
2-3 mg/kg dose equivalent to 25-35 mg/kg in mice.  
Mice (8-12 animals per group) were treated with methylone applying a regimen of 
three subcutaneous doses of 25 mg/kg, with a 3.5 h interval between each injection for 
2 consecutive days (treatment A; total daily dose: 75 mg/kg); or four subcutaneous 
injections of 25 mg/kg in one day with a 3 h interval between each injection (treatment 
B; total daily dose: 100 mg/kg). Another group also received saline (5 ml/kg). Rectal 
temperatures were measured by inserting a lubricated, flexible rectal probe (1.5 cm) 
attached to a digital thermometer (0331 Panlab, Barcelona, Spain) into the rectum. In 
preliminary studies we found that maximum hyperthermia was achieved 45 min after 
administration. However, in order to reduce animal stress we chose to record body 
temperature after the second dose of each day’s treatment. Mice were lightly restrained 
by hand during the procedure, with a steady read-out of temperature obtained 
approximately 40 s after the probe insertion. During the treatments, the animals were 
maintained in an ambient temperature of 26 ± 2ºC and kept under these conditions 
until 1 h after the last daily dose. 
 
Tissue sample preparation 
Crude membrane preparations were prepared as described elsewhere (Escubedo et 
al., 2005) with minor modifications. Mice were killed by cervical dislocation at 3 or 7 
days post-treatment, and the brains were rapidly removed from the skull. 
Hippocampus, striatum, frontal or parietal cortex were quickly dissected out, frozen on 
dry ice, and stored at -80°C until use. When required, tissue samples were thawed and 
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homogenized at 4°C in 20 volumes of buffer consisting of 5 mM Tris-HCl, 320 mM 
sucrose, and protease inhibitors (aprotinin 4.5 µg/µl, 0.1 mM phenylmethylsulfonyl 
fluoride, and 1 mM sodium orthovanadate), pH 7.4. The homogenates were centrifuged 
at 1,000 x g for 15 min at 4°C. Aliquots of the resulting supernatants were stored at -
80ºC until use for Western blot experiments. The rest of the samples were 
resuspended and centrifuged at 15,000 x g for 30 min at 4°C. The pellets were 
resuspended in buffer and incubated at 37ºC for 5 min to remove endogenous 
neurotransmitters. The protein samples were then recentrifuged and washed two more 
times. The final pellets (crude membrane preparation) were resuspended in the 
appropriate buffer and stored at -80°C until use in radioligand binding experiments. 
Protein content was determined using the Bio-Rad Protein Reagent. 
 
DA and 5-HT transporter densities 
The density of DA transporters in striatal or frontal cortex membranes was measured 
by [3H]WIN35428 binding assays. Assays were performed in glass tubes containing 
250 or 500 µl of [3H]WIN35428 diluted in phosphate-buffered 0.32 M sucrose (final 
radioligand concentration, 5 nM) and 50 or 100 µg of membranes, respectively. 
Incubation was done for 2 h at 4°C and non-specific binding was determined in the 
presence of 30 µM bupropion. All incubations were finished by rapid filtration under 
vacuum through GF-B glass fiber filters (Whatman, Maidstone, UK) pre-soaked in 0.5% 
polyethyleneimine. Tubes and filters were washed rapidly three times with 4 ml of ice-
cold buffer, and the radioactivity in the filters was measured by liquid scintillation 
spectrometry. 
The density of 5-HT transporters in the hippocampal and frontal cortex membranes 
was quantified by measuring the specific binding of 0.05 nM [3H]paroxetine after 
incubation with 150 µg of protein at 25ºC for 2 h in a Tris-HCl buffer (50 mM, pH 7.4), 
containing 120 mM NaCl and 5 mM KCl to a final volume of 1.6 ml. Clomipramine (100 
µM) was used to determine non-specific binding. 
 
5-HT2A receptor density 
The density of 5-HT2A receptors in mice parietal or frontal cortex membranes was 
measured by [3H]ketanserin binding assays. Membranes were resuspended in 50 mM 
Tris–HCl buffer, pH 7.4 at 4 °C to a concentration of 1 µg/µl. Assays were performed in 
glass tubes containing 1 nM [3H]ketanserin and 100 µg of membranes. Incubation was 
carried out at 37 °C for 30 min in a 50 mM Tris–HCl buffer to a final volume of 0.5 ml. 
Methysergide (10 µM) was used to determine non-specific binding.  
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Western blotting and immunodetection 
A general Western blotting and immunodetection protocol was used to determine 
tyrosine hydroxylase (TH) and tryptophan hydroxylase 2 (TPH2) levels. For each 
sample, 20 µg of protein was mixed with sample buffer [0.5 M Tris-HCl, pH 6.8, 10% 
glycerol, 2% (w/v) SDS, 5% (v/v) 2-β-mercaptoethanol, 0.05% bromophenol blue, final 
concentrations], boiled for 5 min, and loaded onto a 10% acrylamide gel. Proteins were 
then transferred to polyvinylidene fluoride (PVDF) sheets (Immobilon-P; Millipore, 
USA). PVDF membranes were blocked overnight with 5% defatted milk in Tris-buffered 
saline buffer plus 0.05% Tween-20 and incubated for 2 h at room temperature with a 
primary mouse monoclonal antibody against TH (Transduction Laboratories, Lexington, 
KY, USA) diluted 1:5000 or with a primary rabbit polyclonal antibody against TPH2 
(Millipore, USA) diluted 1:1000. After washing, membranes were incubated with a 
peroxidase-conjugated antimouse IgG antibody (GE Healthcare, Buckinghamshire, UK) 
diluted 1:2500 or with a peroxidase-conjugated antirabbit IgG antibody (GE Healthcare) 
diluted 1:5000. Immunoreactive protein was visualized using a chemoluminescence-
based detection kit following the manufacturer's protocol (Immobilon Western, Millipore, 
USA) and a BioRad ChemiDoc XRS gel documentation system (BioRad 
Labs.,Hercules, CA, USA). Scanned blots were analyzed using BioRad Image Lab 
software and dot densities were expressed as a percentage of those taken from the 
control. Immunodetection of β-actin (mouse monoclonal antibody, dil.1:2500) served as 
a control of load uniformity for each lane and was used to normalize differences in TH 
or TPH2 expression due to protein content. 
 
Immunohistochemistry 
Seven days after treatment B animals were anaesthetized with pentobarbital sodium 
(60 mg/kg) and perfused through the heart with 4% paraformaldehyde in 0.1 M 
phosphate buffer (1 ml/g of body weight). Brains were removed and postfixed for 2 h in 
the same solution, cryoprotected by immersion in 30% sucrose/phosphate buffer 
solution for 24 h and frozen in dry ice-cooled isopentane. Serial coronal sections (30 
µm thick) through the whole brain were cut in a cryostat and collected in phosphate 
buffer solution. Free-floating coronal sections were incubated for 15 min at room 
temperature in H2O2 (0.3% in phosphate buffer with 10% methanol). Thereafter, 
sections were incubated in a blocking solution (1% of fetal bovine serum, and 0.2 M 
glycine plus 0.5% Triton X-100 in phosphate buffer). After blocking with 10% normal 
serum and 0.2% bovine serum albumin, sections were rinsed and incubated overnight 
at 4°C using a monoclonal antibody against fibrillary acidic protein (GFAP, 1:1000) 
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(Dako, Denmark). Following this, sections were washed and incubated with a 
biotinylated secondary antibody (1:200 Sigma-Aldrich) for 2 h at room temperature. 
Afterwards sections were incubated with avidin-biotin-peroxidase complex (ABC; 
1:200; Vector, Burlingame, CA). Peroxidase reaction was developed with 0.05% 
diaminobenzidine in 0.1 M phosphate buffer and 0.02% H2O2, and immunoreacted 
sections were mounted on gelatinized slides. Stained sections were examined under a 
light microscope (Olympus BX61). 
 
Neuronal cell cultures 
Primary neuronal cultures of cerebral cortex were obtained from mouse embryos (E-
16-18). The cerebral cortex was dissected, meninges were removed, and tissue was 
incubated for 20 min in trypsin (0.05%) at 37°C. Trypsin was inactivated with fetal 
bovine serum and tissue was triturated with a fire-polished Pasteur pipette. Dissociate 
cells were washed with phosphate buffer containing 0.6% glucose and centrifuged at 
500 x g for 5 min to remove debris. The cells were redissociated in Neurobasal medium 
(Invitrogen, Carlsbad, CA, USA) with 0.5 mM L-glutamine, sodium bicarbonate (0.04%) 
and 1 µg/ml penicillin and streptomycin, containing B27 supplement and 10% horse 
serum. Neurons were plated at 0.4 million cells/ml in 96-well plates precoated with 1 
mg/mL poly-L-lysine. Cultures were maintained at 37°C in a humidified incubator with 
5% CO2 and 95% air. Twenty-four hours later, cells were treated with 
arabinosylcytosine (10µM) to prevent the growth of glial cells. The culture medium was 
changed every 3 days to Neurobasal medium with B27 without antioxidants and the 
concentration of horse serum was reduced gradually down to 1%. The cultures were 
used for experiments after 8-9 days in vitro with different concentrations of methylone 
(80-1000 µM) and different times of drug exposure (24 and 48 h).  
 
Cell Viability Assay 
Cell viability was assessed by the MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyltetrazoliumbromide) assay. MTT was added to the cells to a final concentration 
of 250 µM and incubated for 2 h (Hansen et al., 1989). The media were removed and 
cells were dissolved in dimethylsulphoxide. Formation of formazan was tested by 
measuring the amount of reaction product by absorbance change (595 nm) using a 
microplate reader (BioRad Laboratories, CA, U.S.A.). Viability results were expressed 
as a percentage of the absorbance measured in untreated cells.  
 
Forced swimming test (FST) 
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The immobility time in the FST was measured by an observer blind to the treatment 
using the procedure described by Porsolt et al. (1978). Briefly, mice were placed 
individually in a glass cylinder (height 21 cm, diameter 12 cm) containing water at 25 ± 
1°C up to a height of 15 cm. Mice do not try to dive or explore the water surface, which 
explains the ease in use of mice that do not need a previous session (Petit-Demouliere 
et al., 2005). Animals were randomly divided into two groups (12-16 animals per group) 
and treated with saline or methylone and tested 3 or 7 days after treatment. Each 
animal was recorded for 6 min and the total period of immobility, in seconds, was 
measured. A mouse was judged to be immobile when it remained floating in water, 
making only the necessary movements to keep its head above water. Each mouse was 
only tested once (Calapai et al., 2001). Increase in the duration of immobility was 
considered to reflect a depressant-like effect of the drug. 
 
Statistical Analysis 
All data are expressed as mean ± standard error of the mean (S.E.M.). Differences 
between groups were compared using one-way ANOVA or Student-t test for 
independent samples where appropriate. Significant (P<0.05) differences were then 
analyzed by Tukey’s post hoc test for multiple means comparisons where appropriate. 
All statistic calculations were performed using Graph Pad Instat (GraphPad Software, 
San Diego, USA).  
 
Results 
Lethality 
Initial experiments were carried out with 4-6 animals per cage (48x25x13 cm). Under 
these conditions, lethality was at an approximately 75% level. Given that, all the 
treatments carried out in this study were performed with a single animal per cage 
(35x14x13 cm) housed 4 days before dosing. 
The number of fatalities of methylone-treated mice was similar in treatment A (of 
about 25%) and treatment B (of about 20%) and occurred 1-2 h after the third or the 
fourth dose. To obtain an accurate cause of death a veterinarian necropsy was 
performed. Immediately after the animal's death, the veterinarian did an overall 
examination of some of the animals, as well as looking at individual organs within the 
body. Final diagnostics evidenced hepatomegaly, and acute hemorrhagic pericarditis 
as the cause of death. 
 
Effect of methylone on body temperature and body weight 
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Mehylone induced a significant increase in the body temperature in treatment A and 
treatment B (Fig. 1A). Since the hyperthermia induced by methylone at the second day 
of treatment A was significantly lower than that induced at the first day, tolerance to 
hyperthermic effects of methylone can be concluded. 
In both treatments, methylone produced significant loss in body weight (Fig. 1B).  
At the end of treatment A methylone-treated animals showed an overall decrease in 
body weight of -0.60 ± 0.16 g.  
 
Effect of methylone on different in vivo markers of DA and 5-HT terminals. 
Treatment A: methylone-treated mice showed a transient decrease in [3H]WIN35428 
specific binding in the frontal cortex that resumed a normal level four days later (Fig. 
2A). This decrease was not accompanied by a change in TH expression (3 days: 
saline: 100.00 ± 22.60%; methylone: 110.06 ± 12.70%; 7 days: saline: 100.00 ± 
11.72%; methylone: 116.00 ± 9.49%).    
In contrast, in the striatum, methylone neither affected [3H]WIN35428 binding 
(saline: 100.00 ± 10.27%; methylone: 94.38 ± 8.20%) nor TH expression (saline: 
100.00 ± 11.10%; methylone: 82.40 ± 4.20%), even after 3 days following the end of 
exposure. Thus no further determinations were performed at 7 days. 
With regards to 5-HT transporters, methylone did not modify [3H]paroxetine binding 
in the frontal cortex (Fig 2B). However, in the hippocampus, methylone induced a slight 
reduction in [3H]paroxetine binding, measured 3 days after treatment, which was 
reverted 4 days later (Fig 2C). The levels of THP2 remained unchanged after the 
treatment (saline: 100.00 ± 3.80%; methylone: 83.20 ± 5.70%, P>0.05). 
Treatment B: As above, methylone treatment induced a transient decrease in the 
specific binding of [3H]WIN35428 of about 27% in the frontal cortex that returned to 
control values four days later (Fig. 3A). Similarly, no changes in TH expression were 
evidenced (3 days: saline: 100.00 ± 24.47%; methylone: 94.75 ± 15.47%; 7 days: 
saline: 100.00 ± 10.52%; methylone: 97.43 ± 29.88%). As in treatment A, methylone 
did not affect any of these dopaminergic markers in the striatum ([3H]WIN35428 
binding: saline, 100.00 ± 7.57%; methylone, 93.91 ± 4.26%. TH expression: saline: 
100.00 ± 3.53%; methylone: 97.06 ± 4.70%; 3 days after drug exposure). 
As regards serotonergic markers, at three and seven days post-treatment, 
methylone induced a diminution of 5-HT reuptake sites of about 30-20% in frontal 
cortex and 20-12% in hippocampus respectively (Fig. 3B and 3C). Additionally, 7 days 
after treatment, TPH2-immunoreactivity levels were decreased in both brain areas in 
the methylone-treated mice that correlates with the diminution of 5-HT reuptake sites 
(Fig. 4A and 4B). 
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Effect of methylone on 5-HT2A receptor density. 
According to the treatment A schedule, methylone-treated, animals showed a decrease 
in the number of 5-HT2A receptors in the frontal (saline: 100.00 ± 4.80%; methylone: 
81.69 ± 2.65%, P<0.01) and parietal cortex (saline: 100.00 ± 4.75%; methylone: 80.60 
± 5.35%, P<0.05), measured as [3H]ketanserin binding, 3 days after treatment, which 
returned to basal values four days later (105.26 ± 10.23% and 119.13 ± 8.49%, 
respectively), pointing to a homeostatic process. In contrast, following schedule B, 
methylone did not modify the density of 5-HT2A receptors in the two cortical areas either 
at 3 (frontal cortex: 85.79 ± 5.40%; parietal cortex: 96.40 ± 3.58%) or 7 days after drug 
exposure (frontal cortex: 111.23 ± 12.96%; parietal cortex: 113.16 ± 3.45%). 
 
Effect of methylone on astroglial activation. 
Because methylone induced neuronal damage 7 days after treatment B schedule, the 
next experiment was carried out to assess the presence of astroglial activation. 
Accordingly, immunohistochemistry studies were performed with the glial-specific 
marker GFAP in brains from animals killed 7 days after the treatment. There were no 
signs of striatal or cortical astroglial activation in methylone-treated animals. However, 
in the hippocampus, an increase in GFAP immunoreactivity was observed in the CA1 
and dentate gyrus of the methylone group, compared with that from saline-tested mice. 
This suggests the presence of a slight reactive astrocytosis (Fig. 5).  
 
Effect of methylone on cultured cortical neuron viability 
The exposure of cultured cortical mouse cells to various concentrations of methylone 
(from 80 µM to 1 mM) for 24 h or 48 h caused a weak concentration- or time-dependent 
decrease in metabolically active cells, as assessed by the MTT assay (Fig. 6). Cell 
viability was only affected by methylone concentrations above 300 µM and the 
corresponding calculated LD50 value for methylone after 24 h or 48 h exposure was 
over 1 mM, ruling out cell toxicity in cortical neurons.  
 
Depressant-like effect of methylone   
Methylone administration (treatments A and B) increased the immobility time in the 
FST 3-day post-treatment as compared with the saline group. This time period 
coincided with the observed impairment of both dopaminergic and serotonergic 
markers. These effects vanished in both schedules one week following drug exposure, 
when only the serotonergic markers remained decreased (Fig. 7). 
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Discussion 
There is little information regarding methylone and its potential toxicity. The initial 
status of cathinones as legal highs may have contributed to their increasing popularity 
as drugs of abuse. Because of the relatively short history of the use of cathinones as 
recreational drugs, their long-term effects have not yet been determined. 
Very few studies exist, even in rodents, on the dosing schedules or doses required 
to induce damage (Baumann et al., 2012; Hollander et al., 2013). Therefore, the 
primary goal of this study was to evaluate the risk of neuronal changes linked to 
methylone abuse in mice. Methylone is a close structural analogue of MDMA, differing 
only by the addition of a β-ketone group. Consequently, it is also known as beta-keto-
MDMA. As with MDMA, it might affect the DA or 5-HT system differently, depending on 
the animal species used for the experiment. Most authors described the maximum 
neurotoxic effects of methamphetamine three days after treatment (Pu and Vorhees, 
1993) and those of MDMA seven days after treatment (Battaglia et al., 1988). Thus, we 
examined the neurotoxic injury induced by methylone at 3 and 7 days after following 
the end of the treatment. In addition, a close relationship was already established 
between the hyperthermic response and the severity of the brain lesion induced by 
amphetamines (Sánchez et al., 2004), supporting the hypothesis that MDMA is 
neurotoxic when a binge dosing schedule is employed and the animals are in a hot 
environment. Accordingly, present experiments were carried out at a high ambient 
temperature simulating hot conditions found in dance clubs. We administered the drug 
at 3-3.5h interval, in accordance with our previous paper characterizing the 
pharmacokinetics of methylone, distinguished by its short half-life (López-Arnau et al., 
2013). To model recreational methylone use, we simulated the widespread practices of 
“stacking” (taking multiple doses at once in order to increase the desired effect and/or 
offset tolerance from prior use) and “boosting” (taking supplemental doses over time in 
order to maintain the drug’s effect). Thus, we chose to administer multiple doses/day of 
methylone during each treatment. 
Overall, our data demonstrate a slight serotonergic toxicity of methylone, one week 
after treatment, only when four doses are administered in a day. This toxicity is 
substantiated by decreases in density of 5-HT terminal marker and reduction in TPH2 
expression, both more apparent in frontal cortex than in hippocampus. Post-mortem 
necropsies showed evident signs of hepatomegaly and hemorrhagic pericarditis that 
could be the cause of death. Further pathology studies are needed to affirm that these 
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signs resulted directly from methylone toxicity but methylone has been described as a 
cause of cardiac arrest leading to human death (Cawrse et al., 2012). 
Our initial experiments indicated that methylone toxicity is exacerbated in group-
housed animals like other amphetamines (Fantigrossi et al., 2003). Baumann et al., 
(2013) already described that, in humans, adverse effects of bath salts could be 
intensified in hot crowded spaces, such as rave party venues where these drugs are 
often used. Present experiments were performed in singly-housed mice. We have 
studied the evolution of body weight during methylone treatments. Like other 
amphetamine derivatives such MDMA, the animals treated with methylone, but not with 
saline, showed a weight loss, probably due to an anorectic effect of the drug.  
Several factors, and particularly hyperthermia, contribute to MDMA-induced 
neurotoxicity. In this regard, the influence of ambient temperature on MDMA-induced 
thermal responses has been shown in earlier studies that noted a hyperthermic 
response when experiments were carried out at high ambient temperatures (26-28°C). 
Hyperthermia is, in fact, a commonly reported acute adverse effect of beta-
ketoamphetamine ingestion in humans (Borek and Holstege, 2012; Prosser and 
Nelson, 2012). In the present study, experiments were performed at ambient 
temperature of 26 ± 2ºC. Under these conditions, methylone induced hyperthermia. 
This effect was more apparent on the first day of treatment and diminished when the 
drug was administered on a second day, indicating the possibility of tolerance that 
could be due to a depletion of neurotransmitter stores.  
 
Following the two treatments performed in this study, methylone induced a 
transient loss of the DA transporter in the frontal cortex. The initial decline and later 
recovery of DA transporter points to a biochemical down-regulation in the absence of 
tissue damage but we can also assume that a methylone-induced dopamine 
transporter structural modification could occur, explaining the reduction in binding 
experiment. This hypothesis is in agreement with our previous results, which 
demonstrate that methylone inhibits [3H]DA uptake after drug withdrawal, pointing to 
alterations in the transporter that are more complex than a simple blocking of the 
carrier (López-Arnau et al., 2013). Unlike MDMA (Chipana et al., 2006), methylone did 
not alter DA transporter radioligand binding or TH levels in striatum in any of the 
performed treatments. The main difference between treatments was found in 5-HT 
terminal markers. When exposure to methylone was performed over two consecutive 
days with three doses per day, we registered a transient reduction of these markers, 
but when treatment consisted of four doses in a single day, a more persistent effect 
appeared, affecting frontal cortex and hippocampus. The final reduction in 5-HT 
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transporter marker correlates with the decrease in TPH2 expression.  Astrocytes 
stabilize and maintain homeostatic tissue repair and contribute to early wound repair 
(Eddleston and Mucke, 1993). In the present study methylone-treated animals with 
schedule B showed an increase in GFAP immunoreactivity in hippocampal CA1 and 
dentate gyrus that corresponds to real terminal injury in these areas.  
Only one study has been published concerning the neurotoxic effect of methylone 
in DA and 5-HT systems in mice (Hollander et al., 2013). Authors demonstrated that 
methylone exposure (30 mg/kg, twice daily for 4 days) had no effect on 
neurotransmitter levels in C57BL/J6 mice two weeks after treatment. Our results 
demonstrate that methylone neurotoxicity in mice depends on the number of doses and 
intervals between each dose, as occurs with other cathinones. Furthermore, we 
suspect that the high room temperature, used in this study, could play an important role 
in methylone-induced neurotoxicity if we compare our findings with those of Hollander 
et al. (2013). Nonetheless, further research is necessary in order to assess whether the 
role of hyperthermia and room temperature is complementary or essential in the advent 
of methylone-induced neurotoxicity. Some differences among neurotoxicity cathinone 
literature can be partially due to differences in the employed dosing-regimen and the 
time of sacrifice. However, due to the mechanism of action and structural similarity 
between methylone and MDMA, we used similar doses and time of sacrifice assessed 
in MDMA neurotoxicity studies (Chipana et al., 2006; Granado et al., 2008; Sánchez et 
al., 2003; Mueller et al., 2013). 
Mice differ from other animal species because they display deficits in DA 
neurotransmission greater than 5-HT after binge MDMA exposure. Present results 
demonstrated that methylone acts on contrary. The methylone neurochemical profile 
could be explained by the fact that this drug acts preferentially as an inhibitor for the 5-
HT transporter than for the DA transporter (Baumann et al., 2012; López-Arnau et al., 
2012; Sogawa et al., 2011), implying a better access of this drug to the 5-HT nerve 
terminals leading to the corresponding injury. Moreover, a well-recognized hypothesis 
of MDMA neurotoxicity involves some metabolite participation that has not been 
demonstrated for methylone.   
 Methylone increased the immobility time in the FST following both treatments, 
which indicates an increase in stress-related depressive behavior. This effect was 
evidenced 3 days after treatment and correlates with the reduction of DA and 5-HT 
markers assayed. This is in accordance with results from McGregor et al. (2003), who 
demonstrated that MDMA-treated animals show a higher immobility and fewer active 
escape attempts in the forced swimming model. To our knowledge, the present studies 
provide the first preclinical data to shed light on this issue, suggesting that mice 
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exposed to a stacking and boosting regime of methylone could be more prone to 
suffering from depressive-like symptoms. This effect disappeared 7 days after 
treatment, when only serotonergic neurotransmission remained impaired. It must be 
noted that depression pathophysiology may also involve changes in 5-HT2 receptor in 
brain regions selectively implicated in mood regulation. In this regard, in treatment A 
we found a significant transient decrease in the number of cortical 5-HT2A receptors 
three days after administration, possibly resulting from a neuroadaptative response to 
the massive 5-HT release induced by methylone. These results hark back to those 
published by Scheffel et al. (1992) regarding MDMA.  In treatment B, we detected a 
similar, but non-significant, reduction in frontal cortex. 
The impairment induced by methylone on 5-HT and DA terminals is limited to 
frontal cortex and hippocampus when exposure is clustered in four doses in a day. This 
mild cathinone neurotoxicity correlates with results of our in vitro studies in cortical 
cultured cells, where we describe that methylone did not show concentration- and time-
dependent deleterious effect on neuronal viability. The data reveal that doses up to 
1000 µM for 24 to 48 h do not appreciably affect cell viability. This is a remarkable 
finding, which confirms previous studies that found methylone alone is not cytotoxic 
even at high doses (Nakagawa et al., 2009; Sogawa et al., 2011). In this regard, other 
studies assessing the effects of MDMA on cortical or hippocampal cultured cell viability 
reported no or low cell death following exposure to high MDMA concentrations (Capela 
et al., 2006). 
In conclusion, our results demonstrate that methylone-induced brain 
consequences differ according to treatment schedule (dose, number of doses and dose 
interval). Neurochemical changes elicited by methylone are apparent when 
administered at an elevated ambient temperature, four times per day at 3h intervals. 
This schedule is related with patterns used by humans and agree with methylone’s 
half-life in rodents (López-Arnau et al., 2013). Following this, we found decrease in 
frontal cortex and hippocampal serotoninergic nerve ending markers around 20-25% 
together with hippocampal astrogliosis suggesting nerve ending injuries. No effect in 
striatum was evidenced. Methylone did not show a cytotoxic effect in cortical cultured 
neurons. The limited neurotoxicity found in this study, however, should not preclude 
advice concerning the high risk of acute fatal effects affecting the cardiovascular 
system and thermoregulation. 
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Legends of Figures 
 
Figure 1.- Effect of methylone treatments A and B in body temperature measured after 
the second dose of each day’s treatment (panel A) and in body weight (panel B; empty 
bars represent saline and striped bars represent methylone). Results are expressed as 
mean ± S.E.M. from 8-10 animals. **P<0.01 and ***P<0.001 vs. saline. ## P<0.01 vs. 
methylone treatment A day 2. 
 
Figure 2.- Effect of a methylone treatment (3 doses of 25 mg/kg, sc at 3.5 h interval for 
2 days) in dopamine transporter density, measured as [3H]WIN35428 binding in mouse 
frontal cortex (panel A) and serotonin transporter density, measured as [3H]paroxetine 
binding in frontal cortex (panel B) and hippocampus (panel C). Results are expressed 
as mean ± S.E.M. from 8-10 animals. *P<0.05 and **P<0.01 vs. saline. 
 
Figure 3.- Effect of a methylone treatment (4 doses of 25 mg/kg, sc at 3 h interval) in 
dopamine transporter density, measured as [3H]WIN35428 binding in mouse frontal 
cortex (panel A) and serotonin transporter density, measured as [3H]paroxetine binding 
in frontal cortex (panel B) and hippocampus (panel C). Results are expressed as mean 
± S.E.M. from 8-10 animals. *P<0.05; **P<0.01 and ***P<0.001 vs. saline. 
 
Figure 4.- Effect of a methylone treatment (4 doses of 25 mg/kg, sc at 3 h interval) on 
tryptophan hydroxylase 2 expression in mouse frontal cortex (panel A) and 
hippocampus (panel B) 7 days after treatment. Below each bar graph, representative 
Western blots of TPH-2 expression in frontal cortex and hippocampus, respectively. 
**P<0.01 and *P<0.05 vs. saline. 
 
Figure 5.- Representative hippocampal expression of glial fibrilliary acidic protein 
(GFAP). Sections of the dentate gyrus from mice treated with saline (panels A and C) 
or methylone (4 doses of 25 mg/kg, sc 3 h interval) (panels B and D). The animals 
were sacrificed 7 days after treatment. 
 
Figure 6.- Effect in cell viability of methylone on mouse cortical cultured neurons. Cells 
were exposed to different concentrations of methylone for 24 or 48 h and cell viability 
was assessed by the MTT assay. Data are expressed as mean ± S.E.M. from 3 
different cultures. 
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Figure 7.- Effect of methylone on immobility time in mouse forced swim test. Animals 
(12-16 animals/group) were randomly divided and treated subcutaneously with saline 
(5 ml/kg) or methylone (3 doses of 25 mg/kg, sc at 3.5 h interval for 2 days (panel A) or 
4 doses of 25 mg/kg, sc 3 h interval (panel B)) and tested 3 or 7 days after treatment. 
Each animal was recorded for 6 min and the total period of immobility was registered. 
Each mouse was used only once for each experimental session. Each bar represents 
mean ± S.E.M. immobility time in seconds. **P<0.01 and *P<0.05 as compared with 
respective saline-treated group (one-way ANOVA and post hoc Tukey’s test). 
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